4D Molecular Therapeutics, Inc.
FDMT
$4.20
-$0.08-1.87%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -66.67% | -40.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -66.67% | -40.00% | |||
| Cost of Revenue | 11.96% | 20.79% | |||
| Gross Profit | -11.97% | -20.80% | |||
| SG&A Expenses | 3.00% | 19.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.74% | 20.43% | |||
| Operating Income | -9.75% | -20.44% | |||
| Income Before Tax | -13.29% | -25.43% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.29% | -25.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.29% | -25.43% | |||
| EBIT | -9.75% | -20.44% | |||
| EBITDA | -10.17% | -21.04% | |||
| EPS Basic | -13.11% | -24.81% | |||
| Normalized Basic EPS | -13.12% | -24.80% | |||
| EPS Diluted | -13.11% | -24.81% | |||
| Normalized Diluted EPS | -13.12% | -24.80% | |||
| Average Basic Shares Outstanding | 0.16% | 0.49% | |||
| Average Diluted Shares Outstanding | 0.16% | 0.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
